who should not take glp 1 medications Guidance from the MHRA, published in June 2025, on weightloss medication 💡Read the full guide here:

TB-500 is being studied for muscle recovery and inflammation, but its lacking robust clinical evidence in humans

Research has shown that since semaglutides can affect the brains reward system, they can weaken the desire for alcohol craving

The trial followed 54 healthy adults over six months, dividing them into a placebo group, a low-dose group (250 mg/day), and a high-dose group (1000 mg/day), meticulously tracking glutathione levels across multiple cellular compartments, as detailed in the published clinical trial

Hair Loss Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use: A Systematic Review. Cureus , vol